Current stock page

Financial Data

EDIT Financial Data

Revenue · Earnings · Margins · Balance Sheet · Cash Flow

HealthcareBiotechnologyScore data as of Sep 4, 2026

EDIT

Financial Data
Editas Medicine, Inc.
Healthcare· Biotechnology
AIQ Score
NeutralAIQ Edge 4/10
Low Priority
In Line With Peers
Score data as of Sep 4, 2026
Last price
$3.23
+$0.15 (+4.87%)
Latest market quote
Momentum70
Value34
Quality53
Risk Resilience39
Sentiment
View financial data

Financial Data Overview

Detailed revenue, earnings, margins, balance sheet, cash flow, valuation metrics, technical indicators, and risk measures for deeper research.

Quarterly periods
8
Fundamental metrics
10
Technical indicators
12
Risk measures
6

Quarterly Financial Statements

Updated Sep 7, 2026.

Income statement
8 periods
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-30
Revenue$11.89M$2.83M$24.74M$7.54M$3.58M$4.66M$30.6M$61K
Gross Profit$11.89M$2.35M$24.74M$7.54M$3.58M$4.66M$30.6M-$1.54M
Operating Income
Net Income-$18.23M-$24.98M-$5.62M-$25.12M-$53.24M-$76.09M-$45.4M-$62.14M
EPS-$0.15-$0.26-$0.06-$0.28-$0.63-$0.92-$0.55-$0.75
Cash flow statement
8 periods
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-30
Operating Cash Flow-$29.57M-$23.06M-$36.39M-$30.84M-$50.21M-$47.8M-$50.76M-$52.59M
Capital Expenditure-$106K-$92K-$60K-$433K$0-$114K-$540K-$2.92M
Free Cash Flow-$29.67M-$23.15M-$36.45M-$31.28M-$50.21M-$47.91M-$51.3M-$55.51M
Net Cash Provided By Operating Activities-$29.57M-$23.06M-$36.39M-$30.84M-$50.21M-$47.8M-$50.76M-$52.59M
Balance sheet
8 periods
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-30
Total Assets$237.36M$149.34M$186.53M$201.75M$210.58M$263.65M$341.59M$327.57M
Total Debt$15.51M$71.97M$76.71M$19.65M$21.14M$31.13M$35.03M$38.49M
Cash And Cash Equivalents
Total Liabilities$132.08M$144.93M$159.25M$188.3M$191.39M$201.23M$207.32M$151.93M
Total Stockholders Equity$105.28M$4.41M$27.29M$13.45M$19.19M$62.42M$134.27M$175.63M
Key financial metrics
8 periods
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-30
P/E ratio-5.4-2.38-8.87-3.11-0.87-0.32-0.58-1.13
P/B ratio3.6754.856.6723.249.681.540.781.6
P/S ratio32.5185.47.3541.4451.920.683.434,611.06
Debt To Equity0.1516.332.811.461.10.50.260.22
Free Cash Flow Yield
Financial ratios
8 periods
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-30
P/E ratio
P/B ratio3.6754.856.6723.249.681.540.781.6
P/S ratio32.5185.47.3541.4451.920.683.434,611.06
Return On Equity-17.32%-5.67%-20.60%-186.70%-277.42%-121.90%-33.81%-35.38%
Debt To Equity

Current Stock Metrics

Current fundamental, technical, and risk readings in one place.

Fundamental metrics
Pe
-4.11
multipleSep 4, 2026
Pb
3.48
multipleSep 4, 2026
Revenue Growth Yoy
319.99
percentSep 4, 2026
EPS Growth Yoy
42.31
percentSep 4, 2026
Gross Margin
56.9
percentSep 4, 2026
Operating Margin
-174.71
percentSep 4, 2026
ROE
-196.63
percentSep 4, 2026
ROIC
-46.81
percentSep 4, 2026
Debt To Equity
0.15
ratioSep 4, 2026
FCF Yield
-25.59
percentSep 4, 2026
Technical indicators
Close
3.23
priceSep 4, 2026
Volume
1,390,713
volumeSep 4, 2026
Rsi14
60.21
indexSep 4, 2026
MACD
0.07
indexSep 4, 2026
MACD Signal
0.06
indexSep 4, 2026
MACD Histogram
0.01
indexSep 4, 2026
Adx14
29.19
indexSep 4, 2026
Sma50
3.02
priceSep 4, 2026
Sma200
2.61
priceSep 4, 2026
Atr14
0.21
priceSep 4, 2026
Historical Volatility
0.82
percentSep 4, 2026
Volume Ma20
2,551,743.25
volumeSep 4, 2026
Risk measures
Resilience Score
39
score_0_100Sep 4, 2026
Beta
2.06
ratioSep 4, 2026
Volatility Annual
85.15
percentSep 4, 2026
Max Drawdown
-59.88
percentSep 4, 2026
Sharpe Ratio
0.67
ratioSep 4, 2026
Var95
-8.12
percentSep 4, 2026

Detailed Metrics

Additional measures remain available here while the decision pages stay focused.

Additional fundamental metrics

No additional fundamental metrics are available.

Additional technical indicators

No additional technical indicators are available.

Additional risk measures

No additional risk measures are available.

EDIT Financial Data FAQ

What is Editas Medicine, Inc.'s revenue?

Editas Medicine, Inc.'s revenue is one of the core financial data points for EDIT. Use it with revenue growth, margins, and EPS to understand whether sales are translating into earnings power.

Is Editas Medicine, Inc.'s revenue growing?

Revenue growth shows whether Editas Medicine, Inc. is expanding from prior periods. Compare growth with margins and free cash flow because faster sales growth is more valuable when profitability holds up.

What is EDIT's EPS?

EDIT's EPS, or earnings per share, helps connect net income to each share. EPS should be compared with EPS growth, P/E ratio, and analyst expectations.

What is Editas Medicine, Inc.'s net income?

Editas Medicine, Inc.'s net income shows profit after costs, taxes, and other expenses. It should be read with revenue, operating margin, EPS, and free cash flow.

How much free cash flow does Editas Medicine, Inc. generate?

Free cash flow shows how much cash Editas Medicine, Inc. generates after capital spending. It is useful for judging reinvestment capacity, buybacks, debt reduction, and valuation support.

How much cash and debt does Editas Medicine, Inc. have?

Cash and debt help frame EDIT's balance-sheet flexibility. Compare liquidity and leverage with free cash flow and profitability before judging financial strength.